YD Bio Ltd — Investor Relations & Filings
Filings indexed
55
across all filing types
Latest filing
2026-03-26
Director's Dealing
Country
US
United States of America
Listing
US
YDES
YD Bio Ltd. is a biotechnology company that develops solutions for early cancer detection and regenerative medicine. The company's primary focus is on creating non-invasive, blood-based diagnostic tests for various cancers, including pancreatic and colorectal, through its OkaiDx™ testing portfolio. In parallel, YD Bio is advancing next-generation cell therapies, utilizing stem cell and exosome-based technologies. These therapeutic initiatives target applications in areas such as ophthalmology, with programs like its LSC Exosome Therapeutics. The company aims to improve patient lives by making its diagnostic and therapeutic innovations accessible.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-26 | English | |
| 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-18 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 424B3 Filing | 2026-02-05 | English | |
| 6-K Filing | 2026-01-30 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-21 | English |
Browse filings by year
3 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 33051985 | 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-26 | English | ||
| 32976484 | 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-18 | English | ||
| 32299107 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32299365 | 424B3 Filing | 2026-02-05 | English | ||
| 32299164 | 6-K Filing | 2026-01-30 | English | ||
| 13691093 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-21 | English | ||
| 13691094 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-16 | English | ||
| 13691095 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-15 | English | ||
| 13691096 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-06 | English | ||
| 13691097 | REGISTRATION STATEMENT | 2026-01-02 | English | ||
|
2025
5 filings
| |||||
| 13691098 | Major Shareholding Notification 2025 | 2025-12-17 | English | ||
| 13691099 | PROSPECTUS | 2025-11-17 | English | ||
| 13691100 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-17 | English | ||
| 13691101 | AMENDMENT NO. 1 TO FORM F-1 | 2025-10-24 | English | ||
| 13691102 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-09-30 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
|
Caliway
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
YD Bio Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32250/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32250 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32250 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32250 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32250}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for YD Bio Ltd (id: 32250)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.